Abbott Partners Spain-Based mAbxience to Commercialise Biosimilars in Emerging Markets

This collaborative move will help introduce life-saving treatments in key oncology, women's health and respiratory diseases for the first time in some countries at a fraction of the cost of originator biologics.

USA's multinational healthcare company, Abbott (ABT) has recently entered into an agreement with the Spain-based biopharmaceutical company, mAbxience Holding SL. This agreement is to commercialise several biosimilar molecules in significant emerging markets across Latin America, Southeast Asia, the Middle East and Africa. 

The collaboration further aims to make these advanced medicines more accessible and affordable in these emerging countries that lack advanced treatments by leveraging Abbott's broad in-country footprint. 

As per the agreement, the bio-pharmaceutical company mAbxience will manufacture biosimilars in one of its two advanced Good Manufacturing Practices approved facilities located in Spain and Argentina. 

This collaborative effort is anticipated to introduce life-saving treatments in areas such as oncology, women's health, and respiratory diseases to certain countries for the first time, all at a fraction of the cost of originator biologics.

Biosimilars, categorised as biotech drugs have shown to have comparable quality, safety, and efficacy as the original product. These can be used to treat a wide range of diseases including cancers. The use of biosimilars in cancer treatment has the potential to manage the disease effectively and improve patient outcomes.

Reportedly, over three-quarters of global deaths resulting from chronic diseases occur in emerging countries. In both Brazil and Mexico, up to 40% of cancer patients who could benefit from biologics fail to receive the required therapy.

Although, Abbott-mAbxience partnership isn't a new one. It dates back to 2018 with Abbott offering access to treatment options involving two advanced oncology biosimilars across several countries, including Colombia, Chile, Peru, and Central America. While mAbxience was responsible for the development, manufacturing, and supply of the necessary biosimilar molecules.

In August, this year, Abbott India also joined forces with Redcliffe Labs to launch 'œAlinIQ", an AI-powered clinical reporting solution to improve the healthcare industry providing solutions to enhance patient care and convenience.

Founded in 1888, USA's Abbott Laboratories help people by bringing new products and technologies in nutrition, diagnostics, medical devices, and branded generic pharmaceuticals. 

While, Spain-based mAbxience Holding SL utilises advanced technology and innovative platforms to deliver integrated manufacturing solutions.